

MEETING AGENDA

EVENT:	Testing Surge Workgroup	Date / Time:	September 25, 2020 @ 1130
Author:	Lindsay Garfinkel, EY	Approved:	October 2, 2020

Enter information below: (text box will automatically expand, numbering is automatic)

Required Attendees (X=Present):

	NCDHHS	<i>Sec. Mandy Cohen</i>	X	NCDHHS	<i>Dr. Betsey Tilson</i>
X	NCDHHS	<i>Dr. Scott Shone</i>		NCDHHS	<i>Dr. Cardra Burns</i>
X	NCDHHS	<i>Dr. Zack Moore</i>	X	NCDHHS	<i>Azzie Conley</i>
	NCDHHS	<i>Amanda Fuller-Moore</i>	X	LabCorp	<i>Traci Butler Clay Gibson</i>
X	Quest	<i>Natalie Jackson Betsey Swider</i>	X	Duke	<i>Dr. Michael Datto</i>
X	MAKO	<i>Josh Arant</i>	X	Atrium Health	<i>Dr. Gerald Capraro</i>
X	UNC Health	<i>Dr. Melissa Miller</i>	X	NC Medical Society	<i>Dr. Garrett Franklin</i>
	Old North State Medical Society	<i>Dr. Charlene Green</i>		NCCHCA	<i>Chris Shank</i>
	Community Rep	<i>Dr. Mark Massing</i>	X	Mecklenburg Cty	<i>Dr. Meg Sullivan</i>
X	NC Board of Pharmacy	<i>Jay Campbell</i>	X	NC Healthcare Association	<i>Dr. John Fallon or Dr. Mary Jo Cagle</i>
X	NCALHD	<i>Stacie Saunders and Lisa Macon Harrison</i>	X	NC Institute of Public Health	<i>Doug Umland</i>
X	Resolve to Save Lives	<i>Marina Smelyanskaya Lyz Ortiz</i>		Guests:	<i>Dr. Aditi Mallick, Natalie Ivanov, Chris Dobbins, Jason Smedberg, Correll McRae, Dana Webb-Randall, Kevin McAvey</i>
X	Manatt (in support of NC DHHS)	<i>Emily Carrier</i>			
X	Ernst & Young (in support of NC DHHS)	<i>Lindsay Garfinkel Marshall Turner, Brian Weeks</i>			

Agenda:

- I. **Welcome and Roll Call**—Dr. Shone (5 min)
- II. **Approval of September 18th Meeting Minutes**—Dr. Shone (5 min)
- III. **Opening Remarks**—Secretary Cohen, if available (5 min)
- IV. **New Business**
 - a. **Test Trends and Hot Topics**—Drs. Tilson, Moore, and Shone (15 min)
 - b. **Antigen Test Deployment Update**—Dr. Aditi Mallick (15 min)

MEETING AGENDA

c. **Open Discussion**—Dr. Shone

V. **Due Outs Assigned and Closing**—Drs. Shone, Tilson or Moore, if available (5 min)

Tasks / Due Outs: (List the recommended lead responsible for each task)

Due Date	Organization POC	Task
10/2	Dr. Scott Shone	Convene the Scientific Council to discuss antigen guidance.

Discussion by Major Topic: (Information not covered on slides or handouts)

I. **Welcome and Roll Call**—Dr. Shone (5 min)

II. **Approval of September 18th Meeting Minutes**—Dr. Shone (5 min)

a. There was a motion and second; the minutes were approved.

III. **Opening Remarks**—Secretary Cohen, if available (5 min)

IV. **New Business**

a. **Test Trends and Hot Topics**—Drs. Tilson, Moore, and Shone (15 min)

i. NC entered Phase 2.5 about 3 weeks ago.

ii. NC has not seen a big surge or a big decline; number of cases have been stable.

iii. Percent positive is decreasing and is ~5%.

iv. If the trends stay stable, NC may move to a Phase 3.

v. NC will be issuing various guidance documents in the near future, such as Halloween guidance.

vi. Starting today (9/25), the public facing dashboard will show tests broken down by molecular and antigen, and deaths associated with a PCR positive or an antigen positive.

b. **Antigen Test Deployment Update**—Dr. Aditi Mallick (15 min)

i. HHS is deploying antigen Abbott BinaxNOW tests to all 50 states – HHS has already sent Abbott BinaxNOW tests to 256 nursing homes, 443 assisted living facilities, and 5 HBCUs in NC.

ii. NC DHHS is unsure of how many antigen tests NC will receive from HHS; anticipating the 2nd wave of distribution coming to NC at earliest next week; to be distributed at the State’s discretion.

iii. Need the Test Surge Workgroup’s feedback on the best populations and areas for antigen deployment.

iv. Scientific Council will convene next week to talk about antigen guidance and will follow up to see if there is any existing EUA data on kids.

v. Pre-decisional discussion followed around the following questions; no decisions were made.

- What circumstances are best suited for this test? (one time vs. ongoing cadence) (congregate settings vs. settings where people come and go).
- What target populations do you think are best suited for this test?

MEETING AGENDA

<ul style="list-style-type: none">· Any use cases that are better for BinaxNOW relative to other antigen tests?· Concerns or challenges you foresee that need to be taken into consideration?<ul style="list-style-type: none">a. Need clear guidance on what to do with a negative test.b. The volume of tests that NC gets determines the answer to some of these questions.c. Need messaging on a population level.c. Open Discussion—Dr. Shone<ul style="list-style-type: none">i. Abbott is re-labeling the Abbott ID Now tests to be similar to the Abbott BinaxNOW tests (antigen tests). <p>V. Due Outs Assigned and Closing—Drs. Shone, Tilson or Moore, if available (5 min)</p> <ul style="list-style-type: none">a. Scientific Council meeting next week.b. Minutes to be sent out early next week.	
Next Meeting:	2 October 2020, 1130-1230 Microsoft Teams Link ; Phone: 984-204-1487, Conference ID: 575 272 672#